or Try an Advanced Search...

    Metastatic Melanoma Stocks List

    Symbol Grade Name % Change
    BMY F Bristol-Myers Squibb Company -1.15
    AGEN D Agenus Inc. -5.58
    IOVA C Iovance Biotherapeutics, Inc. 3.04
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Melanoma Biopharmaceutical Cancer Cancer Treatment Clinical Medicine Medicine Adoptive Cell Transfer Agenus Alzheimer's Disease Antineoplastic Drugs Atrial Fibrillation Biopharmaceutical Products Biotechnology Breast And Lung Cancer Cancer Cell Cancer Immunotherapy Cancer Immunotherapy Product Cancer Vaccine Carcinoma Cell Therapy

    Related ETFs - A few ETFs which own one or more of the above listed Metastatic Melanoma stocks.

    Symbol Grade Name Weight
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 7.38
    MEDX F Horizon Kinetics Medical ETF 5.43
    WBIY D WBI Power Factor High Dividend ETF 4.72
    XPH C SPDR S&P Pharmaceuticals ETF 4.47
    IHE C iShares U.S. Pharmaceutical ETF 4.42
    View all Metastatic Melanoma ETFs...
    Compare ETFs
    Compare FTXH to MEDX Compare FTXH to XPH Compare MEDX to IHE

        Metastatic Melanoma Stocks Recent News

        Date Stock Title
        May 3 BMY Bristol-Myers Squibb: A Lost Decade?
        May 2 BMY Schrodinger gets rights to cancer drug candidate back from Bristol
        May 2 BMY Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
        May 1 BMY Editas, Bristol Myers extend T cell therapy collaboration
        May 1 BMY Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
        May 1 AGEN Agenus regains compliance with Nasdaq minimum bid price requirement
        May 1 AGEN Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
        May 1 IOVA Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
        Apr 30 AGEN Time Is Running Out For Agenus To Raise Cash
        Apr 30 BMY Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
        Apr 30 BMY J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations
        Apr 30 BMY Bristol Myers Squibb: Tough Times Continue
        Apr 29 BMY J&J, Bristol Myers lose challenges to US drug price negotiation program
        Apr 29 IOVA With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
        Apr 29 BMY Bristol Myers, Repertoire to develop tolerizing vaccines in multi-year pact
        Apr 29 BMY Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
        Apr 29 BMY Repertoire pivot pays dividends with Bristol Myers deal
        Apr 29 BMY Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
        Apr 28 BMY Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
        Apr 28 IOVA Where Will Iovance Biotherapeutics Stock Be in 5 Years?
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Melanoma Biopharmaceutical Cancer Cancer Treatment Clinical Medicine Medicine Adoptive Cell Transfer Agenus Alzheimer's Disease Antineoplastic Drugs Atrial Fibrillation Biopharmaceutical Products Biotechnology Breast And Lung Cancer Cancer Cell Cancer Immunotherapy Cancer Immunotherapy Product Cancer Vaccine Carcinoma Cell Therapy
        Metastatic Melanoma

        Metastatic melanoma is a type of skin cancer that has spread to other parts of the body. It is the most advanced form of melanoma and is usually more difficult to treat than earlier stages of the disease. Metastatic melanoma can spread to the lymph nodes, lungs, liver, brain, and other organs. Treatment options may include surgery, radiation, chemotherapy, immunotherapy, and targeted therapy.

        Browse All Tags